Regulation of cancer germline antigen gene expression: Implications for cancer immunotherapy

Future Oncology

Volumn 6, Issue 5, 2010, Pages 717-732

  Akers, Stacey N ^a   Odunsi, Kunle ^a   Karpf, Adam R ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Cancer germline antigen; Cancer testis antigen; Cancer vaccine; DNA hypomethylation; DNA methylation; Epigenetics; Immunotherapy; NY ESO 1

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; CANCER VACCINE; CD133 ANTIGEN; CYCLIC AMP; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; METHYL CPG BINDING PROTEIN; NY ESO 1 ANTIGEN; PROTEIN P53; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR CTCF; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SP1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER GERMLINE ANTIGEN GENE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GLIOMA; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CANCER; MELANOMA; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ANTIGENS, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 77952517187     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.36     Document Type: Review

References (107)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5 (8), 615-625 (2005).
2. Gjerstorff MF, Kock K, Nielsen O, Ditzel HJ: MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum. Reprod. 22 (4), 953-960 (2007).
3. Koslowski M, Bell C, Seitz G et al.: Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res. 64 (17), 5988-5993 (2004).
4. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002).
5. Hofmann O, Caballero OL, Stevenson BJ et al.: Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105 (51), 20422-20427 (2008). • Comprehensive survey of cancer germline antigen gene expression in normal tissues and cancer.
6. Karpf AR: Cancer germline antigens. In: Encyclopedia of cancer (2nd Edition). Schwab M (Ed.). Springer-Verlag, Berlin, Germany, 478-479 (2008).
7. Almeida LG, Sakabe NJ, Deoliveira AR et al.: CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 37 (Database issue), D816-D819 (2009).
8. Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).
9. Van Der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (5038), 1643-1647 (1991).
10. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S: An overview of the MAGE gene family with the identifcation of all human members of the family. Cancer Res. 61 (14), 5544-5551 (2001).
11. Smith IM, Glazer CA, Mithani SK et al.: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS ONE 4 (3), E4961 (2009). • Demonstrates that CG antigen genes are activated and hypomethylated in conjunction with BORIS expression in a subset of human tumors.
12. Glazer CA, Smith IM, Ochs MF et al.: Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS ONE 4 (12), E8189 (2009).
13. Odunsi K, Jungbluth AA, Stockert E et al.: NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63 (18), 6076-6083 (2003).
14. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR: Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specifc and global DNA methylation status in ovarian cancer. Clin. Cancer Res. 14 (11), 3283-3290 (2008). •• Demonstrates that heterogeneous expression of CG antigens in individual tumors in vivo correlates with epigenetic states.
15. Gjerstorff M, Burns JS, Nielsen O, Kassem M, Ditzel H: Epigenetic modulation of cancergermline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. Am. J. Pathol. 175 (1), 314-323 (2009). •• Reveals mechanisms involved in CG antigen gene regulation in cancer stem cells.
16. Karpf AR: A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine effcacy Epigenetics 1 (3), 116-120 (2006).
17. Berger Sl, Kouzarides T, Shiekhattar R, Shilatifard A: An operational defnition of epigenetics. Genes Dev. 23 (7), 781-783 (2009).
18. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93 (14), 7149-7153 (1996).
19. De Smet C, Lurquin C, Lethe B, Martelange V Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specifc genes with a CpG-rich promoter Mol. Cell. Biol. 19 (11), 7327-7335 (1999).
20. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21 (35), 5400-5413 (2002).
21. Weber J, Salgaller M, Samid D et al.: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 54 (7), 1766-1771 (1994).
22. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol. Pharm. 65 (1), 18-27 (2004).
23. Illingworth RS, Bird AP: CpG islands - 'a rough guide'. FEBS Lett. 583 (11), 1713-1720 (2009).
24. Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21 (35), 5496-5503 (2002).
25. Wischnewski F, Friese O, Pantel K, Schwarzenbach H: Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol. Cancer Res. 5 (7), 749-759 (2007).
26. Morgan HD, Santos F, Green K, Dean W, Reik W: Epigenetic reprogramming in mammals. Hum. Mol. Genet. 14 (1), R47-R58 (2005).
27. Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 20 (24), 3139-3155 (2001).
28. James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3B. Oncogene 25 (52), 6975-6985 (2006).
29. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7, 21 (2007).
30. Loriot A, De Plaen E, Boon T, De Smet C: Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem. 281 (15), 10118-10126 (2006).
31. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM: Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol. Cancer Res. 7 (4), 523-535 (2009). • Reveals a mechanism by which activation of a CG antigen promotes a specifc oncogenic phenotype: evolution to castration recurrent prostate cancer.
32. Wischnewski F, Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and-A12 in human cancer cells. Mol. Cancer Res. 4 (5), 339-349 (2006).
33. Link PA, Gangisetty O, James SR et al.: Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol. Cancer Res. 7 (6), 851-862 (2009).
34. Jenuwein T, Allis CD: Translating the histone code. Science 293 (5532), 1074-1080 (2001).
35. Lin W, Dent SY: Functions of histonemodifying enzymes in development. Curr. Opin. Genet. Dev. 16 (2), 137-142 (2006).
36. Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifcations. Mol. Cancer Ther. 8 (6), 1409-1420 (2009).
37. + tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58 (3), 383-394 (2009). • Provides evidence that adoptive T-cell-transfer-based immunotherapy is augmented by epigenetic therapy.
38. Weiser TS, Guo ZS, Ohnmacht GA et al.: Sequential 5-aza-2 deoxycytidinedepsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specifc for NY-ESO-1. J. Immunother. 24 (2), 151-161 (2001).
39. Lachner M, O'Sullivan RJ, Jenuwein T: An epigenetic road map for histone lysine methylation. J. Cell. Sci. 116 (Pt 11), 2117-2124 (2003).
40. Tachibana M, Sugimoto K, Nozaki M et al.: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16 (14), 1779-1791 (2002).
41. Tachibana M, Ueda J, Fukuda M et al.: Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19 (7), 815-826 (2005).
42. Dong KB, Maksakova IA, Mohn F et al.: DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J. 27 (20), 2691-2701 (2008).
43. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y: G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J. 27 (20), 2681-2690 (2008).
44. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q: Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther. 8 (12), 3191-3202 (2009).
45. Sigalotti L, Fratta E, Coral S et al.: Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is me thy lat ion-regulated and functionally reverted by 5-aza-2'- deoxycytidine. Cancer Res. 64 (24), 9167-9171 (2004).
46. Loriot A, Sterpin C, De Backer O, De Smet C: Mouse embryonic stem cells induce targeted DNA demethylation within human MAGE-A1 transgenes. Epigenetics 3 (1), 38-42 (2008).
47. Costa FF, Le Blanc K, Brodin B: Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25 (3), 707-711 (2007).
48. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B: Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 65 (6), 2207-2215 (2005).
49. Loriot A, Reister S, Parvizi GK, Lysy PA, De Smet C: DNA methylation-associated repression of cancer-germline genes in human embryonic and adult stem cells. Stem Cells 27 (4), 822-824 (2009).
50. Sigalotti L, Covre A, Zabierowski S et al.: Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell Physiol. 215 (2), 287-291 (2008).
51. Gedye C, Quirk J, Browning J et al.: Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol. Immunother. 58 (10), 1635-1646 (2009). •• Reports that CD133+ melanoma stem cells show enhanced CG antigen gene expression, which is further selected for by chemotherapy, and can be effectively targeted by NY-ESO-1-specifc cytotoxic T lymphocytes.
52. Yawata T, Nakai E, Park KC et al.: Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol. Carcinog. (2010) (Epub ahead of print).
53. De Smet C, Courtois SJ, Faraoni I et al.: Involvement of two ETS binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 42 (4), 282-290 (1995).
54. Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F: Methylated CpG points identifed within MAGE-1 promoter are involved in gene repression. Int. J. Cancer 68 (4), 464-470 (1996).
55. Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J: Activation of the early B-cell-specifc MB-1 (IG-α) gene by PAX-5 is dependent on an unmethylated ETS binding site. Mol. Cell. Biol. 23 (6), 1946-1960 (2003).
56. Klenova EM, Morse HC III, Ohlsson R, Lobanenkov VV: The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin. Cancer Biol. 12 (5), 399-414 (2002).
57. Loukinov DI, Pugacheva E, Vatolin S et al.: BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl Acad. Sci. USA 99 (10), 6806-6811 (2002).
58. Hong JA, Kang Y, Abdullaev Z et al.: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 65 (17), 7763-7774 (2005).
59. Vatolin S, Abdullaev Z, Pack SD et al.: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res. 65 (17), 7751-7762 (2005). • Implicates the CTCF paralog BORIS as a global regulator of CG antigen gene expression.
60. Nguyen P, Bar-Sela G, Sun L et al.: BAT3 and SET1a form a complex with CTCFl/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol. Cell. Biol. 28 (21), 6720-6729 (2008).
61. Hoffmann MJ, Muller M, Engers R, Schulz WA: Epigenetic control of CTCFl/BORIS and OCT4 expression in urogenital malignancies. Biochem. Pharmacol. 72 (11), 1577-1588 (2006).
62. Rousseaux S, Khochbin S: New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specifc regulators. Epigenomics 1 (1), 153-161 (2009).
63. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C: Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int. J. Cancer 122 (4), 777-784 (2007).
64. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20 (6), 1692-1703 (2002).
65. Hoei-Hansen CE, Kraggerud SM, Abeler VM et al.: Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol. Cancer 6, 12 (2007).
66. Yang B, Wu J, Maddodi N, Ma Y, Setaluri V, Longley BJ: Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J. Invest. Dermatol. 127 (9), 2123-2128 (2007).
67. Kondo T, Zhu X, Asa SL, Ezzat S: The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fbroblast growth factor receptor 2-IIIb through histone H3 modifcations in thyroid cancer. Clin. Cancer Res. 13 (16), 4713-4720 (2007).
68. Zhu X, Asa SL, Ezzat S: Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifcations targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res. 14 (7), 1984-1996 (2008). • Illustrates how specifc transcription factors and signal transduction molecules interact with epigenetic states to regulate CG antigen gene expression.
69. Monte M, Simonatto M, Peche LY et al.: MAGE-A tumor antigens target p53 trans activation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103 (30), 11160-11165 (2006).
70. Yang B, O'Herrin SM, Wu J et al.: MAGE-A, mMAGE-B, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67 (20), 9954-9962 (2007).
71. Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 26 (30), 4394-4403 (2007).
72. Renaud S, Pugacheva EM, Delgado MD et al.: Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res. 35 (21), 7372-7388 (2007).
73. Bai S, Grossman G, Yuan L et al.: Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol. Hum. Reprod. 14 (2), 107-116 (2008).
74. Sabbatini P, Odunsi K: Immunologic approaches to ovarian cancer treatment. J. Clin. Oncol. 25 (20), 2884-2893 (2007).
75. + T cell responses in humans. Proc. Natl Acad. Sci. USA 101 (29), 10697-10702 (2004).
76. Chen YT, Scanlan MJ, Sahin U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94 (5), 1914-1918 (1997).
77. Jager E, Nagata Y, Gnjatic S et al.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 97 (9), 4760-4765 (2000).
78. Stockert E, Jager E, Chen YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187 (8), 1349-1354 (1998).
79. Jager E, Chen YT, Drijfhout JW et al.: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: defnition of human histocompatibility leukocyte antigen (HLA) -A2-binding peptide epitopes. J. Exp. Med. 187 (2), 265-270 (1998).
80. Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M: Identifcation of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specifc antitumor immune response. Clin. Cancer Res. 10 (3), 890-896 (2004).
81. Sharma P, Gnjatic S, Jungbluth AA et al.: Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 3, 19 (2003).
82. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191 (4), 625-630 (2000).
83. + T cells. Cancer Res. 60 (17), 4946-4952 (2000).
84. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165 (2), 1153-1159 (2000).
85. + T cells by a single peptide with dual MHC class I and class II specifcities: a new strategy for vaccine design. Cancer Res. 62 (13), 3630-3635 (2002).
86. Cheever MA, Allison JP, Ferris AS et al.: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15 (17), 5323-5337 (2009).
87. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
88. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95 (17), 10067-10071 (1998).
89. Uyttenhove C, Pilotte L, Theate I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med. 9 (10), 1269-1274 (2003).
90. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 (10), 5211-5218 (1999).
91. Terabe M, Berzofsky JA: Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16 (2), 157-162 (2004).
92. Terabe M, Matsui S, Noben-Trauth N et al.: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (6), 515-520 (2000).
93. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (6990), 457-463 (2004).
94. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L: Epigenetic targets for immune intervention in human malignancies. Oncogene 22 (42), 6484-6488 (2003).
95. Coral S, Sigalotti L, Colizzi F et al.: Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J. Cell. Physiol. 207 (1), 58-66 (2006).
96. Sigalotti L, Altomonte M, Colizzi F et al.: 5-aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101 (11), 4644-4646;
97. discussion 4645-4646 (2003).
98. Schrump DS, Fischette MR, Nguyen DM et al.: Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 12 (19), 5777-5785 (2006). •• Demonstrates that decitabine therapy activates CG antigen gene expression and immune responses in cancer patients.
99. Fonsatti E, Nicolay HJ, Sigalotti L et al.: Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 13 (11), 3333-3338 (2007).
100. Adair SJ, Hogan KT: Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother. 58 (4), 589-601 (2009).
101. Lake RA, Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5 (5), 397-405 (2005).
102. Sfkakis PP, Gourgoulis GM, Moulopoulos LA, Kouvatseas G, Theoflopoulos AN, Dimopoulos MA: Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur. J. Clin. Invest. 35 (6), 380-387 (2005).
103. Matei DE, Nephew KP: Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 116 (2), 195-201 (2010).
104. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (10), 2346-2357 (2005).
105. Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9 (5), 702-708 (1997).
106. Riddell SR, Warren EH, Gavin MA et al.: Immunotherapy of human viral and malignant diseases with genetically modifed T-cell clones. Cancer J. Sci. Am. 6 (Suppl. 3), S250-S258 (2000).
107. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (5796), 126-129 (2006).